Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Central Garden & Pet Company is a packaged foods business based in the US. Central Garden-and-Pet Company shares (CENT) are listed on the NASDAQ and all prices are listed in US Dollars. Central Garden-and-Pet Company employs 7,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$50.56|
|52-week range||$36.53 - $62.91|
|50-day moving average||$46.97|
|200-day moving average||$51.80|
|Wall St. target price||$53.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$3.06|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||2.27%|
|1 month (2021-09-23)||5.36%|
|3 months (2021-07-23)||1.53%|
|6 months (2021-04-23)||-11.47%|
|1 year (2020-10-23)||21.83%|
|2 years (2019-10-23)||71.27%|
|3 years (2018-10-23)||57.46%|
|5 years (2016-10-21)||105.86%|
Valuing Central Garden-and-Pet Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Central Garden-and-Pet Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Central Garden-and-Pet Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Central Garden-and-Pet Company shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Central Garden-and-Pet Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Central Garden-and-Pet Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Central Garden-and-Pet Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $341.2 million.
The EBITDA is a measure of a Central Garden-and-Pet Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.2 billion|
|Operating margin TTM||8.41%|
|Gross profit TTM||$796.6 million|
|Return on assets TTM||6.33%|
|Return on equity TTM||14.73%|
|Market capitalisation||$2.6 billion|
TTM: trailing 12 months
There are currently 630,838 Central Garden-and-Pet Company shares held short by investors – that's known as Central Garden-and-Pet Company's "short interest". This figure is 8.3% up from 582,400 last month.
There are a few different ways that this level of interest in shorting Central Garden-and-Pet Company shares can be evaluated.
Central Garden-and-Pet Company's "short interest ratio" (SIR) is the quantity of Central Garden-and-Pet Company shares currently shorted divided by the average quantity of Central Garden-and-Pet Company shares traded daily (recently around 72426.865671642). Central Garden-and-Pet Company's SIR currently stands at 8.71. In other words for every 100,000 Central Garden-and-Pet Company shares traded daily on the market, roughly 8710 shares are currently held short.
However Central Garden-and-Pet Company's short interest can also be evaluated against the total number of Central Garden-and-Pet Company shares, or, against the total number of tradable Central Garden-and-Pet Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Central Garden-and-Pet Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Central Garden-and-Pet Company shares in existence, roughly 10 shares are currently held short) or 0.0127% of the tradable shares (for every 100,000 tradable Central Garden-and-Pet Company shares, roughly 13 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Central Garden-and-Pet Company.
Find out more about how you can short Central Garden-and-Pet Company stock.
We're not expecting Central Garden-and-Pet Company to pay a dividend over the next 12 months.
Over the last 12 months, Central Garden-and-Pet Company's shares have ranged in value from as little as $36.53 up to $62.91. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Central Garden-and-Pet Company's is 0.5582. This would suggest that Central Garden-and-Pet Company's shares are less volatile than average (for this exchange).
Central Garden & Pet Company produces and distributes various products for the lawn and garden, and pet supplies markets in the United States. It provides pet supplies products, including edible chews and treats, dog chew toys, dog play toys, natural dog treats and chews, pet dental chews and solutions, dog training pads, pet containment, grooming supplies, and other accessories; products for birds, small animals, and specialty pets comprising food, cages and habitats, toys, chews, and related accessories; animal and household health and insect control products; live fish and products for fish, reptiles, and other aquarium-based pets, such as aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food, and supplements; and products for horses and livestock, as well as outdoor cushions and pillows. The company sells its pet supplies products under the Aqueon, Cadet, Comfort Zone, Farnam, Four Paws, Kaytee, K&H Pet Products, Nylabone, and Zilla brands, as well as under Adams, Altosid, Arden Companies, Coralife, C&S Products, Interpet, Pet Select, TFH, and Zodiac other brands. It also offers lawn and garden supplies products that include grass seed; wild bird feed, bird feeders, bird houses, and other birding accessories; fertilizers; decorative outdoor lifestyle products; live plants; and weed and grass, as well as other herbicides, insecticide, and pesticide products. The company sells its lawn and garden supplies products under the AMDRO, Ironite, Pennington, and Sevin brands, as well as under Bell Nursery, Lilly Miller, and Over-N-Out other brand names. Central Garden & Pet Company was founded in 1955 and is based in Walnut Creek, California. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.